Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25907165 | 0.75 | GAA (0.30) | GAA | |
| SCHEMBL26022716 | 0.74 | TRPV1 (0.36) | MEN1KMT2A | |
| SCHEMBL8469793 | 0.73 | ALDH1A1 (0.39) | MEN1KMT2A | |
| SCHEMBL23384915 | 0.70 | APLNR (0.31) | — | |
| SCHEMBL20903678 | 0.69 | EPHX1 (0.51) | MEN1KMT2A | |
| SCHEMBL23793651 | 0.66 | FLT3 (0.31) | — | |
| SCHEMBL20464452 | 0.66 | MTNR1A (0.40) | MEN1KMT2AGAA | |
| SCHEMBL25952839 | 0.66 | MTNR1A (0.40) | MEN1KMT2AGAA | |
| SCHEMBL14671365 | 0.66 | TRPV1 (0.42) | — | |
| SCHEMBL26050242 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | MEN1 457/4885KMT2A 4715/4885GAA 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.